Jiangsu Hengrui Medicine Co. Ltd., of Lianyungang, China, and the University of Texas MD Anderson Cancer Center said they entered a three-year agreement for translational research to develop rational combination therapies and personalized medicines as well as to identify new treatment opportunities, especially in the field of immuno-oncology.